Arvee Laboratories jumps 20% and hits the upper circuit
The company’s shares have delivered an impressive return of 50% to their shareholders during the past six months.
Arvee Laboratories (India) Limited is engaged in producing diverse chemical compounds classified into three primary categories: polymer modifiers, contrast media intermediates, and drug intermediates. Today, the company experienced a significant surge in its share price.
At the start of the day’s trading session, the stock opened at Rs 190.20 per share, indicating an approximate 20% increase compared to the previous day’s closing figure of Rs 158.50 per share on the BSE. As of the time of writing this article, the shares are currently at Rs 190.20 per share on the BSE. The stock has reached the upper circuit price limit of 20%, reflecting strong demand in the market with no sellers willing to offer shares, resulting in potential buyers being unable to make purchases, leading to disappointment among buyers.
The company’s current market capitalisation stands at Rs 209 crore, and the stock has generated an impressive return of 30% during the month and a 50% return in the past six months.
Trading and Delivery Volumes (Daily):
Business Overview
Arvee Laboratories (India) Limited, based in India, specializes in manufacturing various types of chemicals. The company offers products in three main categories: polymer modifiers, contrast media intermediates, and drug intermediates. Within its polymer modifiers line, it produces compounds like Dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic Acid Mono Sodium Salt, 5-sulfoisophthalic Acid Mono Lithium Salt, and 5-sodiosulfo-bis-(B-Hydroxyethyl)-Isophthalate. In the realm of contrast media intermediates, the company provides substances such as 5-nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-hydroxyisophthalic acid, 5-Aminoisophthalic acid, Dimethyl 5-Aminoisophthalate, and 3,5-Diamino Benzoic Acid. Additionally, its drug intermediates portfolio encompasses products like 2-acetyl Thiophene, Thiophene-2-Carboxaldehyde, 4-amino Pyridine, and 2-chloro-5-nitrobenzoic Acid.
Financial Performance
In the second quarter of FY24, the company reported revenues of Rs 8.9 crore, marking a decline of 61% compared to the same quarter in the previous year when the revenue stood at Rs 22.74 crore. The company recorded an operating profit of Rs 0.69 crore for the quarter, a contrast to the operating profit of Rs 3.26 crore in the corresponding quarter of the previous year. Additionally, the company reported a net profit of Rs 0.21 crore compared to Rs 2.05 crore in the same period last year. However, it’s worth noting that both the top line and bottom line of the company declined in the recent quarter compared to the same quarter the previous year.
The company’s ROCE and ROE stand at 23.3% and 15.8% respectively, while the shares are trading at a PE of 129 times in the market.
Stock Price Chart (Weekly)
Disclaimer: This post has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.